Literature DB >> 10225552

The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis.

A C Begg1, K Haustermans, A A Hart, S Dische, M Saunders, B Zackrisson, H Gustaffson, P Coucke, N Paschoud, M Hoyer, J Overgaard, P Antognoni, A Richetti, J Bourhis, H Bartelink, J C Horiot, R Corvo, W Giaretti, H Awwad, T Shouman, T Jouffroy, Z Maciorowski, W Dobrowsky, H Struikmans, G D Wilson.   

Abstract

PURPOSE: The aim of this study was to assess the potential of pre-treatment cell kinetic parameters to predict outcome in head and neck cancer patients treated by conventional radiotherapy.
MATERIALS AND METHODS: Data from 11 different centers were pooled. Inclusion criteria were such that the patients received radiotherapy alone, and that the radiotherapy was given in an overall time of at least 6 weeks with a dose of at least 60 Gy. All patients received a tracer dose of either iododeoxyuridine (IdUrd) or bromodeoxyuridine (BrdUrd) intravenously prior to treatment and a tumor biopsy was taken several hours later. The cell kinetic parameters labeling index (LI), DNA synthesis time (Ts) and potential doubling time (Tpot) were subsequently calculated from flow cytometry data, obtained on the biopsies using antibodies against I/BrdUrd incorporated into DNA. Each center carried out their own flow cytometry analysis.
RESULTS: From the 11 centers, a total of 476 patients conforming to the inclusion criteria were analyzed. Median values for overall time and total dose were 49 days and 69 Gy, respectively. Fifty one percent of patients had local recurrences and 53% patients had died, the majority from their disease. Median follow-up was 20 months; being 30 months for surviving patients. Multivariate analysis revealed that T-stage, maximum tumor diameter, differentiation grade, N-stage, tumor localization and overall time correlated with locoregional control, in decreasing order of significance. For the cell kinetic parameters, univariate analysis showed that only LI was significantly associated with local control (P=0.02), with higher values correlating with a worse outcome. Ts showed some evidence that patients with longer values did worse, but this was not significant (P=0.06). Tpot showed no trend (P=0.8). When assessing survival in a univariate analysis, neither LI nor Tpot associated with outcome (P=0.4, 0.4, respectively). Surprisingly, Ts did correlate with survival, with longer values being worse (P=0.02). In the multivariate analysis of local control, LI lost its significance (P=0.16).
CONCLUSIONS: The only pretreatment kinetic parameter for which some evidence was found for an association with local control (the best end-point for testing the present hypothesis) was LI, not Tpot, and this evidence disappeared in a multivariate analysis. It therefore appears that pretreatment cell kinetic measurements carried out using flow cytometry, only provide a relatively weak predictor of outcome after radiotherapy in head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225552     DOI: 10.1016/s0167-8140(98)00147-9

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  23 in total

1.  Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.

Authors:  W M Harriss-Phillips; E Bezak; E K Yeoh
Journal:  Br J Radiol       Date:  2011-10       Impact factor: 3.039

2.  Molecular biology: the key to personalised treatment in radiation oncology?

Authors:  D G Hirst; T Robson
Journal:  Br J Radiol       Date:  2010-09       Impact factor: 3.039

Review 3.  Predicting outcomes in radiation oncology--multifactorial decision support systems.

Authors:  Philippe Lambin; Ruud G P M van Stiphout; Maud H W Starmans; Emmanuel Rios-Velazquez; Georgi Nalbantov; Hugo J W L Aerts; Erik Roelofs; Wouter van Elmpt; Paul C Boutros; Pierluigi Granone; Vincenzo Valentini; Adrian C Begg; Dirk De Ruysscher; Andre Dekker
Journal:  Nat Rev Clin Oncol       Date:  2012-11-20       Impact factor: 66.675

Review 4.  Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.

Authors:  Janice Cho; Daniel E Johnson; Jennifer R Grandis
Journal:  Semin Radiat Oncol       Date:  2018-01       Impact factor: 5.934

5.  Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Michael A Deveau; Lyndsay Kubicek; Pamela White; Søren M Bentzen; Richard J Chappell; Lisa J Forrest; Robert Jeraj
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-15       Impact factor: 7.038

6.  Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.

Authors:  Natalie M Lowe; Jonathan M Bernstein; Kathleen Mais; Kate Garcez; Lip W Lee; Andrew Sykes; David J Thomson; Jarrod J Homer; Catharine M West; Nicholas J Slevin
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-08       Impact factor: 4.553

Review 7.  Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy.

Authors:  In Ja Park; Chang Sik Yu
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

8.  Predictive value of modelled tumour control probability based on individual measurements of in vitro radiosensitivity and potential doubling time.

Authors:  M Hedman; T Björk-Eriksson; O Brodin; I Toma-Dasu
Journal:  Br J Radiol       Date:  2013-03-11       Impact factor: 3.039

9.  Importance of tumor volume in supraglottic and glottic laryngeal carcinoma.

Authors:  L W van Bockel; E M Monninkhof; F A Pameijer; C H J Terhaard
Journal:  Strahlenther Onkol       Date:  2013-11-08       Impact factor: 3.621

10.  Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types.

Authors:  M H W Starmans; B Krishnapuram; H Steck; H Horlings; D S A Nuyten; M J van de Vijver; R Seigneuric; F M Buffa; A L Harris; B G Wouters; P Lambin
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.